Heron Therapeutics (HRTX) Competitors $1.19 -0.05 (-4.03%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends HRTX vs. NGM, GBIO, MRSN, RVNC, EOLS, STOK, NUVB, TRDA, ANNX, and TRMLShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include NGM Biopharmaceuticals (NGM), Generation Bio (GBIO), Mersana Therapeutics (MRSN), Revance Therapeutics (RVNC), Evolus (EOLS), Stoke Therapeutics (STOK), Nuvation Bio (NUVB), Entrada Therapeutics (TRDA), Annexon (ANNX), and Tourmaline Bio (TRML). These companies are all part of the "medical" sector. Heron Therapeutics vs. NGM Biopharmaceuticals Generation Bio Mersana Therapeutics Revance Therapeutics Evolus Stoke Therapeutics Nuvation Bio Entrada Therapeutics Annexon Tourmaline Bio Heron Therapeutics (NASDAQ:HRTX) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations. Do analysts rate HRTX or NGM? Heron Therapeutics currently has a consensus price target of $5.67, indicating a potential upside of 376.19%. NGM Biopharmaceuticals has a consensus price target of $2.53, indicating a potential upside of 63.96%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Heron Therapeutics is more favorable than NGM Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00NGM Biopharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer HRTX or NGM? In the previous week, Heron Therapeutics had 20 more articles in the media than NGM Biopharmaceuticals. MarketBeat recorded 20 mentions for Heron Therapeutics and 0 mentions for NGM Biopharmaceuticals. Heron Therapeutics' average media sentiment score of 0.24 beat NGM Biopharmaceuticals' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Heron Therapeutics Neutral NGM Biopharmaceuticals Neutral Does the MarketBeat Community prefer HRTX or NGM? Heron Therapeutics received 630 more outperform votes than NGM Biopharmaceuticals when rated by MarketBeat users. Likewise, 69.17% of users gave Heron Therapeutics an outperform vote while only 60.38% of users gave NGM Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformHeron TherapeuticsOutperform Votes66269.17% Underperform Votes29530.83% NGM BiopharmaceuticalsOutperform Votes3260.38% Underperform Votes2139.62% Is HRTX or NGM more profitable? Heron Therapeutics has a net margin of -20.31% compared to NGM Biopharmaceuticals' net margin of -3,223.34%. Heron Therapeutics' return on equity of 0.00% beat NGM Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Heron Therapeutics-20.31% N/A -12.72% NGM Biopharmaceuticals -3,223.34%-77.85%-67.76% Which has preferable earnings & valuation, HRTX or NGM? Heron Therapeutics has higher revenue and earnings than NGM Biopharmaceuticals. Heron Therapeutics is trading at a lower price-to-earnings ratio than NGM Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeron Therapeutics$137.74M1.31-$110.56M-$0.18-6.61NGM Biopharmaceuticals$4.42M29.10-$142.38M-$1.72-0.90 Which has more volatility and risk, HRTX or NGM? Heron Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Do institutionals and insiders hold more shares of HRTX or NGM? 80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 75.7% of NGM Biopharmaceuticals shares are owned by institutional investors. 5.8% of Heron Therapeutics shares are owned by insiders. Comparatively, 35.9% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryHeron Therapeutics beats NGM Biopharmaceuticals on 15 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$180.99M$6.39B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E Ratio-6.6110.92101.9217.45Price / Sales1.31245.131,198.0869.07Price / CashN/A53.4940.9736.36Price / Book-4.589.306.335.87Net Income-$110.56M$154.14M$119.64M$225.66M7 Day Performance-32.00%-9.47%-5.13%-1.34%1 Month Performance-34.62%-7.30%-2.72%1.15%1 Year Performance9.17%28.21%31.08%24.02% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics4.0402 of 5 stars$1.19-4.0%$5.67+376.2%+29.8%$180.99M$137.74M-6.61300Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageNGMNGM Biopharmaceuticals3.5585 of 5 stars$1.54-1.3%N/A+155.2%$128.53M$4.42M-0.90138GBIOGeneration Bio3.5351 of 5 stars$1.68-8.2%N/A+37.5%$112.21M$5.90M-0.77150Positive NewsMRSNMersana Therapeutics4.3148 of 5 stars$2.52-4.2%N/A+43.5%$309.14M$29.94M-2.90150Analyst ForecastAnalyst RevisionNews CoverageRVNCRevance Therapeutics3.8657 of 5 stars$4.31+1.7%N/A-39.7%$452.12M$234.04M-2.23597EOLSEvolus4.105 of 5 stars$11.88-3.0%N/A+34.3%$752.25M$248.33M-13.05170Short Interest ↑STOKStoke Therapeutics3.9035 of 5 stars$13.92+0.1%N/A+188.5%$737.30M$16.74M-6.63100News CoverageNUVBNuvation Bio2.3415 of 5 stars$2.88-2.7%N/A+101.5%$716.57MN/A-1.3260TRDAEntrada Therapeutics2.3061 of 5 stars$19.04-4.6%N/A+16.1%$712.48M$129.01M11.97110Insider SellingANNXAnnexon2.7007 of 5 stars$6.33-3.4%N/A+139.1%$692.03MN/A-5.1560Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageTRMLTourmaline Bio1.9857 of 5 stars$26.88+2.4%N/A+53.9%$689.20MN/A-9.5344Analyst RevisionNews Coverage Related Companies and Tools Related Companies NGM Biopharmaceuticals Competitors Generation Bio Competitors Mersana Therapeutics Competitors Revance Therapeutics Competitors Evolus Competitors Stoke Therapeutics Competitors Nuvation Bio Competitors Entrada Therapeutics Competitors Annexon Competitors Tourmaline Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HRTX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
